Biogen (BIIB)
(Delayed Data from NSDQ)
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Zacks News
AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib
by Zacks Equity Research
AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug
by Zacks Equity Research
Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.
Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU
by Zacks Equity Research
Roche's (RHHBY) investigational oral medicine risdiplam gets PRIME designation for the treatment of SMA.
5 Incredible ETFs & Stocks to Buy on the Dip
by Sweta Killa
The dips might charge up investors to snap up stocks and ETFs on the cheap for outsized gains heading into Christmas.
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
by Zacks Equity Research
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
by Zacks Equity Research
A low key week for the biotech sector with focus on regular pipeline updates.
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
4 Biotech Stocks Investors Can Add to Their Portfolio in 2019
by Ekta Bagri
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis
by Zacks Equity Research
Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.
FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.
AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
by Zacks Equity Research
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.
Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
by Zacks Equity Research
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.
5 Top Stocks to Make the Most of a Divided Congress
by Tirthankar Chakraborty
Gridlock in Washington bodes well for healthcare and defense stocks, which calls for investing in such a space for the time being.
Election Day 2018: Here Are the Winners & Losers
by Tirthankar Chakraborty
One of the most awaited midterm elections in American history is upon us. Let's thus look at the sectors most likely to be impacted by the election results.
Biotech ETFs in Focus on String of Q3 Earnings Beat
by Zacks Equity Research
Biotech ETFs draw attention post impressive Q3 results.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret are expected to drive third-quarter sales.
Top Research Reports for McDonald's, Thermo Fisher & Caterpillar
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Thermo Fisher (TMO) and Caterpillar (CAT).
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
by Zacks Equity Research
Earnings releases and key data-read outs were the key developments in the biotech sector last week.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines
by Zacks Equity Research
Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.